The Critical Role Of Excipients In GLP-1 Agonist Formulation Design

GLP-1 agonists introduce formulation challenges that place excipient selection at the center of dosage form performance. For solid dosage forms, targeted intestinal release may help address barriers such as low solubility and limited absorption. Experts share results from the use of a carrier excipient designed to support intestinal delivery, with a close look at solubility and dosage form design. For liquid formulations, granulated buffers can support formulation requirements.

Explore the formulation results and their implications for future GLP-1 development.